A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASH

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and tolerability of HSK31679 compared to placebo in patients with metabolic dysfunction-associated steatohepatitis (MASH) .
Epistemonikos ID: 2feefe542728ba117c7896f0a7339462844c4660
First added on: May 13, 2026